THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)

Lobbying for THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)

Filing 4th Quarter - Amendment

4th Quarter (Oct 1 - Dec 31) 2025 · District of Columbia · House · Senate · $1,670,000.00 expenses · posted Apr 20, 2026

Official filing document

Bills named in this filing 9

S 864
HELP Copays Act
HR 247
Health Care Affordability Act of 2025
HR 3838
Streamlining Procurement for Effective Execution and Delivery and National Defense Authorization Act for Fiscal Year 20…
S 2296
National Defense Authorization Act for Fiscal Year 2026
S 1542
Uyghur Policy Act of 2025
HR 2214
DRUG Act
HR 5378
Tribal Healthcare Careers Act
S 1339
Stop CCP Money Laundering Act of 2025
S 526
Pharmacy Benefit Manager Transparency Act of 2025

Lobbying activity 5

Medicare/Medicaid

Issues related to prior authorization.

Health Issues

S. 864/H.R. 247, the Health Care Affordability Act of 2025 and issues relating to extension of Enhanced Advanced Premium Tax Credits (EAPTCs) including in the American Rescue Plan Act (ARPA) and the Inflation Reduction Act (IRA); Issues relating to implementation of the No Surprises Act.

Defense

H.R. 3838/S. 2296 Pharmacy issues related to the National Defense Authorization Act, FY2026.

Pharmacy

"S. 1542/H.R.2214, the DRUG Act; H.R. 5378 Lower Costs, More Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.526, Pharmacy Benefit Manager Transparency Act." Issues related to the specialty drug market. Issues related to transparency.

Labor Issues/Antitrust/Workplace

Issues related to competition in the health care marketplace.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.